LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.5
(1.29%)
TWD 23.5
(1.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.81 Million TWD | 109.66% |
| 2022 | -116.85 Million TWD | -274.85% |
| 2021 | 65.26 Million TWD | 1401.34% |
| 2020 | -3.05 Million TWD | -116.75% |
| 2019 | 29.93 Million TWD | 32.69% |
| 2018 | 20.3 Million TWD | -81.76% |
| 2017 | 119.55 Million TWD | 10.26% |
| 2016 | 107.8 Million TWD | 421.49% |
| 2015 | -38.74 Million TWD | -154.29% |
| 2014 | 62.58 Million TWD | -83.24% |
| 2013 | 383.57 Million TWD | 2216.28% |
| 2012 | -24.28 Million TWD | -137.81% |
| 2011 | 36.88 Million TWD | 189.92% |
| 2010 | 165.81 Million TWD | -86.24% |
| 2009 | 113.85 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -22.69 Million TWD | -692.66% |
| 2024 Q2 | -10.52 Million TWD | 147.5% |
| 2024 Q1 | -8.62 Million TWD | -157.34% |
| 2023 Q3 | -13.37 Million TWD | -72.14% |
| 2023 Q2 | -7.77 Million TWD | -145.85% |
| 2023 Q1 | 16.94 Million TWD | 254.19% |
| 2023 FY | - TWD | 109.66% |
| 2023 Q4 | 15.22 Million TWD | 213.84% |
| 2022 Q2 | -76.39 Million TWD | -2905.27% |
| 2022 FY | - TWD | -274.85% |
| 2022 Q4 | -10.99 Million TWD | -8.23% |
| 2022 Q1 | -2.54 Million TWD | -122.22% |
| 2022 Q3 | -10.15 Million TWD | 86.71% |
| 2021 FY | - TWD | 1401.34% |
| 2021 Q1 | 14.43 Million TWD | 68.26% |
| 2021 Q2 | 124.25 Million TWD | 760.91% |
| 2021 Q3 | -84.86 Million TWD | -168.3% |
| 2021 Q4 | 11.44 Million TWD | 113.48% |
| 2020 Q2 | 16.93 Million TWD | 234.4% |
| 2020 Q1 | -12.6 Million TWD | -1061.1% |
| 2020 FY | - TWD | -116.75% |
| 2020 Q4 | 8.57 Million TWD | 147.85% |
| 2020 Q3 | -17.92 Million TWD | -205.86% |
| 2019 FY | - TWD | 32.69% |
| 2019 Q2 | -3.51 Million TWD | -115.56% |
| 2019 Q3 | 9.55 Million TWD | 371.92% |
| 2019 Q1 | 22.58 Million TWD | 45.05% |
| 2019 Q4 | 1.31 Million TWD | -86.28% |
| 2018 Q3 | -15.9 Million TWD | -366.1% |
| 2018 Q2 | -3.41 Million TWD | -112.97% |
| 2018 Q4 | 15.57 Million TWD | 197.88% |
| 2018 FY | - TWD | -81.76% |
| 2018 Q1 | 26.31 Million TWD | -30.59% |
| 2017 Q4 | 37.9 Million TWD | -9.14% |
| 2017 Q1 | 53.78 Million TWD | 213.17% |
| 2017 Q2 | -9.71 Million TWD | -118.06% |
| 2017 Q3 | 41.72 Million TWD | 529.44% |
| 2017 FY | - TWD | 10.26% |
| 2016 Q4 | 17.17 Million TWD | -58.91% |
| 2016 Q1 | 35.62 Million TWD | 263.31% |
| 2016 FY | - TWD | 421.49% |
| 2016 Q2 | 17.59 Million TWD | -50.61% |
| 2016 Q3 | 41.79 Million TWD | 137.53% |
| 2015 Q1 | -3.21 Million TWD | -20.98% |
| 2015 FY | - TWD | -154.29% |
| 2015 Q4 | -21.81 Million TWD | -283.51% |
| 2015 Q3 | -5.68 Million TWD | -36.04% |
| 2015 Q2 | -4.18 Million TWD | -30.17% |
| 2014 Q4 | -2.65 Million TWD | -151.09% |
| 2014 FY | - TWD | -83.24% |
| 2014 Q1 | 40.85 Million TWD | 34.76% |
| 2014 Q2 | 20.87 Million TWD | -48.91% |
| 2014 Q3 | 5.19 Million TWD | -75.1% |
| 2013 Q4 | 30.31 Million TWD | -76.72% |
| 2013 FY | - TWD | 2216.28% |
| 2013 Q1 | 116.01 Million TWD | 7781.66% |
| 2013 Q2 | 106.97 Million TWD | -7.79% |
| 2013 Q3 | 130.26 Million TWD | 21.77% |
| 2012 Q3 | -39.59 Million TWD | -372.93% |
| 2012 Q1 | 9.65 Million TWD | -56.95% |
| 2012 FY | - TWD | -137.81% |
| 2012 Q4 | 1.47 Million TWD | 103.72% |
| 2012 Q2 | 14.5 Million TWD | 50.34% |
| 2011 Q2 | -22.7 Million TWD | -200.44% |
| 2011 Q3 | 25.61 Million TWD | 212.82% |
| 2011 Q4 | 22.41 Million TWD | -12.49% |
| 2011 FY | - TWD | 189.92% |
| 2011 Q1 | 22.6 Million TWD | 173.35% |
| 2010 Q2 | -5.94 Million TWD | -126.61% |
| 2010 FY | - TWD | -86.24% |
| 2010 Q3 | -8.12 Million TWD | -36.71% |
| 2010 Q1 | 22.32 Million TWD | 0.0% |
| 2010 Q4 | 8.27 Million TWD | 201.82% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Grape King Bio Ltd | 2.88 Billion TWD | 99.764% |
| Standard Chem & Pharm CO., LTD. | 1.57 Billion TWD | 99.569% |
| Maywufa Company Ltd. | 239.81 Million TWD | 97.16% |
| ScinoPharm Taiwan, Ltd. | 819.15 Million TWD | 99.169% |
| Lotus Pharmaceutical Co., Ltd. | 6.87 Billion TWD | 99.901% |
| YungShin Global Holding Corporation | 1.35 Billion TWD | 99.498% |
| PhytoHealth Corporation | -20.69 Million TWD | 132.902% |
| SCI Pharmtech, Inc. | 529.61 Million TWD | 98.714% |
| Formosa Laboratories, Inc. | 1.16 Billion TWD | 99.415% |
| PharmaEssentia Corporation | -671.48 Million TWD | 101.014% |
| Bora Pharmaceuticals Co., LTD. | 5.73 Billion TWD | 99.881% |